Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tumor-infiltrating Lymphocytes
100%
Single Center
100%
Programmed Death-ligand 1 (PD-L1)
100%
Glioma Patients
100%
PD-L1 Expression
60%
Overall Survival
40%
Glioblastoma multiforme
40%
Putative Drug Targets
20%
Immunohistochemistry
20%
Primary Tumor
20%
Combined Modality Therapy
20%
Newly Diagnosed
20%
Routine Assessment
20%
Cancer Cells
20%
Promoter Methylation
20%
Immune Response
20%
Brain Tumor
20%
Glioblastoma
20%
Brain Metastases
20%
High Density
20%
Cancer Therapy
20%
Dismal Prognosis
20%
Methylation Status
20%
Temozolamide
20%
O6-methylguanine-DNA Methyltransferase
20%
Response Predictors
20%
Tumor Expression
20%
Primary Glioblastoma
20%
Isocitrate Dehydrogenase 1 (IDH1)
20%
CD3+
20%
Immune Microenvironment
20%
Antitumor Immune Response
20%
CD3+ T Cells
20%
NewHope
20%
Radiotherapy Adjuvant
20%
Accurate Predictor
20%
Immune Modulatory Therapies
20%
Medicine and Dentistry
Glioblastoma
100%
CD3 Antigen
100%
Programmed Death-Ligand 1
100%
Tumor Infiltrating Lymphocyte
83%
Overall Survival
33%
Immunotherapy
33%
Immune Response
33%
Cancer
16%
Neoplasm
16%
Immunohistochemistry
16%
Primary Tumor
16%
Recurrent Disease
16%
T Cell
16%
Cancer Therapy
16%
Cancer Cell
16%
Intracranial Tumor
16%
Promoter Region
16%
Adjuvant Radiotherapy
16%
Brain Metastasis
16%
Methylation
16%
6 O Methylguanine
16%
Hope
16%
Methyltransferase
16%
Immune Microenvironment
16%
Immunology and Microbiology
CD3 Antigen
100%
Programmed Death-Ligand 1
100%
Tumor-Infiltrating Lymphocytes
83%
Immune Response
33%
Immunotherapy
33%
Overall Survival
33%
T Cell
16%
Cancer Cell
16%
Promoter Region
16%
Methylation
16%
Immune Microenvironment
16%
Neuroscience
Lymphocyte
100%
CD3 Antigen
100%
Glioblastoma Multiforme
40%
Immunotherapy
40%
Immunohistochemistry
20%
T Cell
20%
Promoter Region
20%
Radiation Therapy
20%
Intracranial Tumor
20%
Methylation
20%
6-O-Methylguanine
20%
Methyltransferase
20%
Immune Microenvironment
20%